Clinical Trials Browser

Phase 2 × OTHER × Non-Small Cell Lung Cancer Metastatic × Clear all

NCT06106802 2026-02-23

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Phase 2 Recruiting

Non-Small Cell Lung Cancer Metastatic

NCT04163432 2025-12-05

STAGGER

Phase 2 Active not recruiting

Non-Small Cell Lung Cancer Metastatic

NCT04646824 2020-12-02

Almonertinib With Chemotherapy in mEGFR NSCLC

Phase 2 Unknown

Non-Small Cell Lung Cancer Metastatic